Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-03-13
2008-05-06
Gaeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S314700
Reexamination Certificate
active
07368465
ABSTRACT:
Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
REFERENCES:
patent: 2745875 (1956-05-01), Ehrhart et al.
patent: 3452040 (1969-06-01), Langis
patent: 3529019 (1970-09-01), Suh et al.
patent: 3849574 (1974-11-01), Suh et al.
patent: 4241073 (1980-12-01), Jamieson et al.
patent: 4315031 (1982-02-01), Vincent et al.
patent: 5068187 (1991-11-01), Takeichi et al.
patent: 5246943 (1993-09-01), Blankley et al.
patent: 5308853 (1994-05-01), Hodges et al.
patent: 5521187 (1996-05-01), Freyne et al.
patent: 5804593 (1998-09-01), Warpehoski et al.
patent: 5917790 (1999-06-01), Ohta et al.
patent: 5955435 (1999-09-01), Baxter et al.
patent: 6046214 (2000-04-01), Kristiansen et al.
patent: 6048841 (2000-04-01), Baxter et al.
patent: 6114361 (2000-09-01), Robinson et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6166041 (2000-12-01), Cavalla et al.
patent: 6218418 (2001-04-01), Pevarello et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6277987 (2001-08-01), Kukkola et al.
patent: 6291685 (2001-09-01), Junghans et al.
patent: 6329418 (2001-12-01), Cheng et al.
patent: 6339101 (2002-01-01), Ross et al.
patent: 6340691 (2002-01-01), Levin et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6890915 (2005-05-01), Sheppeck et al.
patent: 6906053 (2005-06-01), Sheppeck et al.
patent: 7078424 (2006-07-01), Hamilton et al.
patent: 2002/0006920 (2002-01-01), Robinson et al.
patent: 2002/0028835 (2002-03-01), Hu et al.
patent: 2002/0065219 (2002-05-01), Naidu et al.
patent: 2002/0071107 (2002-07-01), Madar et al.
patent: 2003/0130273 (2003-07-01), Sheppeck et al.
patent: 2004/0106659 (2004-06-01), Rosenschold
patent: 2004/0110809 (2004-06-01), Lepisto et al.
patent: 2004/0116486 (2004-06-01), Lepisto et al.
patent: 2004/0127528 (2004-07-01), Eriksson et al.
patent: 2004/0147573 (2004-07-01), Eriksson et al.
patent: 2004/0152697 (2004-08-01), Chan et al.
patent: 2004/0209874 (2004-10-01), Sheppeck et al.
patent: 2005/0019994 (2005-01-01), Chang
patent: 2005/0026990 (2005-02-01), Eriksson et al.
patent: 2005/0171096 (2005-08-01), Sheppeck et al.
patent: 2005/0245586 (2005-11-01), Henriksson et al.
patent: 2005/0256176 (2005-11-01), Burrows et al.
patent: 2006/0063818 (2006-03-01), Burrows et al.
patent: 2006/0276524 (2006-12-01), Henriksson et al.
patent: 212617 (1986-08-01), None
patent: 0486280 (1991-11-01), None
patent: 0 640 594 (1995-03-01), None
patent: 0709375 (1995-10-01), None
patent: 1149843 (2001-10-01), None
patent: 1191024 (2002-03-01), None
patent: 1117616 (2003-04-01), None
patent: 02 74 1724 (2004-03-01), None
patent: WO95/14025 (1994-11-01), None
patent: WO96/27583 (1996-09-01), None
patent: WO98/50359 (1998-05-01), None
patent: WO99/06361 (1999-02-01), None
patent: WO99/42443 (1999-02-01), None
patent: WO99/24399 (1999-05-01), None
patent: WO 00/09103 (2000-02-01), None
patent: WO 00/12477 (2000-03-01), None
patent: WO 00/12478 (2000-03-01), None
patent: WO 00/35886 (2000-06-01), None
patent: WO 00/40577 (2000-07-01), None
patent: WO00/044770 (2000-08-01), None
patent: WO 00/75106 (2000-12-01), None
patent: WO 01/05756 (2001-01-01), None
patent: WO 01/12189 (2001-02-01), None
patent: WO 01/22363 (2001-03-01), None
patent: WO 01/34573 (2001-05-01), None
patent: WO 02/06232 (2002-01-01), None
patent: WO 02/14262 (2002-02-01), None
patent: WO 02/14354 (2002-02-01), None
patent: WO 02/20515 (2002-03-01), None
patent: WO 02/074749 (2002-09-01), None
patent: WO 02/074751 (2002-09-01), None
patent: WO 02/074752 (2002-09-01), None
patent: WO 02/074767 (2002-09-01), None
patent: WO 02074748 (2002-09-01), None
patent: WO 02074750 (2002-09-01), None
patent: WO 02/096426 (2002-12-01), None
patent: WO 03/040098 (2003-05-01), None
patent: WO2004/020415 (2004-03-01), None
patent: WO 2004/024060 (2004-03-01), None
patent: WO 2004/024698 (2004-03-01), None
patent: WO2004/024718 (2004-03-01), None
patent: WO2004/024721 (2004-03-01), None
patent: WO06/004532 (2006-01-01), None
patent: WO06/004533 (2006-01-01), None
Gramatica, et al., STN International, HCAPLUS Database, Columbus, OH, Accession No. 2002:356947, Reg. No. 36734-19-7 (2006).
Hautamaki et al., Science, vol. 277, pp. 2002-2004 (1997).
Wernicke et al., J. Rheumatol., vol. 23, pp. 590-595 (1996).
Whittaker et al., “Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors,” Chem. Rev., vol. 99, pp. 2735-2776 (1999).
Pyo et al., J. Clinical Investigation, vol. 105, No. 11, pp. 1641-1649 (2000).
Doherty et al., Expert Opinion Ther. Patents, vol. 12, pp. 665-707 (2002).
Aharony et al. “Pharmacological Characterization of a New Class of Nonpeptide Neurokinin A Antagonists that Demonstrate Species Selectivity.” J. Pharmacol. Exp. Ther. 274:3 (1995), pp. 1216-1221.
Aimoto et al. “Synthesis of Carriers of Differing Strokes Radius with Activated Acyl Groups for Use as Reagents in Labeling Membrane Proteins.” Journal of Biological Chemistry, vol. 256(10), pp. 5134-5143, 1981.
Croce, P. et al. “Stereoselective aldol addition of a chirai glycine enloate synthon to heteroaromatic aldehydes.” Heterocycles, 52:3 (2000) pp. 1337-1344.
Knabe, J. “Razemate und enantiomere basisch substituierter 5-phenylhydantoine.” Pharmazie. 52:12 (1997) pp. 912-919.
Bright et al. “Monoclonal Antibodies as Surrogate Receptors in High Throughput Screen for Compounds that Enhance Insulin Sensitivity.” Life Sciences. 61:23 (1997), pp. 2305-2315.
Lora-Tamayo et al. “Anticancerousos Potenciales.” An. Quim. 64:6 (1968), pp. 591-606.
Michaelides et al., “Recent Advances in Matrix Metalloproteinase Inhibitors Research”,Current Pharmaceutical Design5:787-819 (1999).
Miyake, Toshiaki et al. “Studies on Glycosylation of erythro-Beta-Hydroxy-L-histidine. A Key Step of Blemycin Total Synthesis.” Bull. Chem. Soc. Jpn. 59 (1986), pp. 1387-1395.
Mock et al., “Principles of Hydroxamate Inhibition of Metalloproteases: Carboxypeptidase A”,Biochemistry39:13945-13952 (2000).
Nakajima, Riichiro et al. “The utility of 4-(2-thienyl)pyridines as a derivatization reagent for hplc and ce.” Analytical Sciences. 7, Supplement 1991, pp. 177-180.
Nicolet, Ben. “Interpretation of the Dyhydration of Acetylglutamic acid by Means of Glutamylthiohydantoin Derivatives.” Journal of the American Chemical Society, 1930, pp. 1192-1195.
Owa, Takashi et al. “Man-Designed Bleomycins: Significance of the binding Sites as Enzyme Models and of the Stereochemistry of the Linker Moiety.” Tetrahedron. 48:7 (1992) pp. 1193-1208.
Peng, Sean X. “Separation and identification of methods for metalloproteinase inhibitors.” Joural of Chromatography B. 764 (2001), pp. 59-80.
Saito, Sei-ichi et al. “A new synthesis of deglyco-bleomycine A2 aiming at the total synthesis of bleomycin.” Tetrahedron Letters. 23(5) (1982), pp. 529-532.
STN International, file CAPLUS, accession No. 1978:424767, Raulais, Daniel J.P., “Synthesis and characterization of phenylthiohydantoin derivatives of amino-acids protected in their sid-chain functions, and their application for monitoring olid-phase peptide synthesis,” & Journal of Chemical Research, Synopses (1978), p. 11.
STN International, File CAPLUS, Caplus accession No. 1968:506154, Doc. No. 69:106154, Lora-Tamayo, J. et al.: “Potential anticancer agents, VI. Sulfonic analogs of aspartic acid”, & An. Quim. (1968), 64(6), 591-606.
STN International, file CAPLUS, accession No. 1994:299315, Document No. 120:299315, Sakamoto, Shuichi et al., “Preparation of pyridylserine derivatives as psychotropics,” WO, A1, 9320053, 19931014, See CAS RN 154696-31-8, 154697-48-0.
STN International, file CAPLUS, accession No. 1997:644516, Batty, Craig et al. “Synthesis and exchange reaction of 5-alkyl-2oxo-6-thioxo-1,2,3,6-hexahydropyrimidine-4-carboxylic acids” & Journal of Heterocyclic Chemistry (1997),
Af Rosenschöld Magnus Munck
Eriksson Anders
Lepistö Matti
Lundkvist Michael
Zlatoidsky Pavol
AstraZeneca AB
Gaeed Kamal A.
Nolan Jason M.
LandOfFree
Metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981492